Peter J.  Wilkinson net worth and biography

Peter Wilkinson Biography and Net Worth

Senior Vice President and Chief Accounting Officer

What is Peter J. Wilkinson's net worth?

The estimated net worth of Peter J. Wilkinson is at least $457,386.92 as of November 16th, 2023. Mr. Wilkinson owns 2,087 shares of Laboratory Co. of America stock worth more than $457,387 as of February 26th. This net worth estimate does not reflect any other investments that Mr. Wilkinson may own. Learn More about Peter J. Wilkinson's net worth.

How old is Peter J. Wilkinson?

Mr. Wilkinson is currently 52 years old. There are 8 older executives and no younger executives at Laboratory Co. of America. The oldest executive at Laboratory Co. of America is Dr. Marcia T. Eisenberg Ph.D., Chief Scientific Officer & Senior VP, who is 65 years old. Learn More on Peter J. Wilkinson's age.

How do I contact Peter J. Wilkinson?

The corporate mailing address for Mr. Wilkinson and other Laboratory Co. of America executives is 358 South Main Street, BURLINGTON NC, 27215. Laboratory Co. of America can also be reached via phone at (336) 229-1127 and via email at [email protected]. Learn More on Peter J. Wilkinson's contact information.

Has Peter J. Wilkinson been buying or selling shares of Laboratory Co. of America?

Peter J. Wilkinson has not been actively trading shares of Laboratory Co. of America during the last ninety days. Most recently, Peter J. Wilkinson sold 1,384 shares of the business's stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $210.71, for a transaction totalling $291,622.64. Following the completion of the sale, the chief accounting officer now directly owns 2,087 shares of the company's stock, valued at $439,751.77. Learn More on Peter J. Wilkinson's trading history.

Who are Laboratory Co. of America's active insiders?

Laboratory Co. of America's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Brian Caveney (EVP), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Laboratory Co. of America's active insiders.

Are insiders buying or selling shares of Laboratory Co. of America?

During the last year, insiders at the medical research company sold shares 10 times. They sold a total of 51,793 shares worth more than $11,208,958.28. The most recent insider tranaction occured on February, 21st when CFO Glenn A Eisenberg sold 34,504 shares worth more than $7,451,828.88. Insiders at Laboratory Co. of America own 0.7% of the company. Learn More about insider trades at Laboratory Co. of America.

Information on this page was last updated on 2/21/2024.

Peter J. Wilkinson Insider Trading History at Laboratory Co. of America

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2023Sell1,384$210.71$291,622.642,087View SEC Filing Icon  
8/1/2022Sell2,576$258.40$665,638.401,887View SEC Filing Icon  
2/18/2021Sell2,317$241.51$559,578.67710View SEC Filing Icon  
2/21/2020Sell297$189.65$56,326.05297View SEC Filing Icon  
See Full Table

Peter J. Wilkinson Buying and Selling Activity at Laboratory Co. of America

This chart shows Peter J Wilkinson's buying and selling at Laboratory Co. of America by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Laboratory Co. of America Company Overview

Laboratory Co. of America logo
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Read More

Today's Range

Now: $217.81
Low: $217.81
High: $217.81

50 Day Range

MA: $223.81
Low: $215.65
High: $232.56

2 Week Range

Now: $217.81
Low: $174.20
High: $234.09

Volume

227 shs

Average Volume

692,238 shs

Market Capitalization

$18.49 billion

P/E Ratio

46.64

Dividend Yield

1.31%

Beta

1.04